Apimeds Pharmaceuticals US, Inc

. Entry into a Material Definitive Agreement. On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (the “Company”) consummated its initial public offering (the “IP

. Unregistered Sales of Equity Securities. In connection with the closing of the IPO, three convertible promissory notes (as amended, the “Notes”) automatically

Regulation FD Disclosure. On May 8, 2025, the Company issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, an

Financial Statements and Exhibits. ‌ (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated May 8, 2025, between the Company and D. Boral Capita